---
document_datetime: 2025-10-14 14:42:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/vaxelis-epar-all-authorised-presentations_en.pdf
document_name: vaxelis-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.2936858
conversion_datetime: 2025-12-20 15:17:25.414029
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form      | Route of Administration   | Immediate Packaging        | Content (concentration)   | Pack size                                 |
|------------------|-------------------|------------|--------------------------|---------------------------|----------------------------|---------------------------|-------------------------------------------|
| EU/1/15/1079/001 | Vaxelis           | --¹        | Suspension for injection | Intramuscular use         | pre-filled syringe (glass) | 0.5 ml                    | 1 pre-filled syringe                      |
| EU/1/15/1079/002 | Vaxelis           | --¹        | Suspension for injection | Intramuscular use         | pre-filled syringe (glass) | 0.5 ml                    | 10 pre-filled syringes                    |
| EU/1/15/1079/003 | Vaxelis           | --¹        | Suspension for injection | Intramuscular use         | pre-filled syringe (glass) | 0.5 ml                    | 1 pre-filled syringe + 1 needle           |
| EU/1/15/1079/004 | Vaxelis           | --¹        | Suspension for injection | Intramuscular use         | pre-filled syringe (glass) | 0.5 ml                    | 1 pre-filled syringe + 2 needles          |
| EU/1/15/1079/005 | Vaxelis           | --¹        | Suspension for injection | Intramuscular use         | pre-filled syringe (glass) | 0.5 ml                    | 10 pre-filled syringes + 10 needles       |
| EU/1/15/1079/006 | Vaxelis           | --¹        | Suspension for injection | Intramuscular use         | pre-filled syringe (glass) | 0.5 ml                    | 10 pre-filled syringes + 20 needles       |
| EU/1/15/1079/007 | Vaxelis           | --¹        | Suspension for injection | Intramuscular use         | pre-filled syringe (glass) | 0.5 ml                    | 50 (5x10) pre-filled syringes (multipack) |

--¹ One dose (0.5 ml) contains: Diphtheria Toxoid¹: not less than 20 IU 6 Tetanus Toxoid¹: not less than 40 IU 6 Bordetella pertussis antigens¹: Pertussis Toxoid (PT) 20 micrograms Filamentous Haemagglutinin (FHA) 20 micrograms Pertactin (PRN) 3 micrograms Fimbriae Types 2 and 3 (FIM) 5 micrograms Hepatitis B surface antigen²,³: 10 micrograms Poliovirus (Inactivated) 4 : Type 1 (Mahoney) 29 D antigen units 5 ; Type 2 (MEF-1) 7 D antigen units 5 Type 3 (Saukett) 26 D antigen units 5 Haemophilus inf luenzae type b polysaccharide (Polyribosylribitol Phosphate) 3 micrograms Conjugated to meningococcal protein² 50 micrograms ¹ adsorbed on aluminium phosphate (0.17 mg Al³+) ² adsorbed on amorphous aluminium hydroxyphosphate sulfate (0.15 mg Al³+) ³ produced in yeast ( Saccharomyces cerevisiae ) cells by recombinant DNA technology 4  produced in Vero cells 5  These antigen quantities are strictly the same as those previously expressed as 40-8-32 D-antigen units, for virus type 1, 2 and 3 respectively, when measured by another suitable immunochemical method 6  or equivalent activity determined by an immunogenicity evaluation.